This article initially appeared in Banker & Tradesman on August 23, 2020.

What: Vertex Cell and Genetic Therapies center
Where: 6 Tide St., Boston
Owner: Related Beal
Built: 2020-2021 

Boston-based architecture firm Tria has been selected to design Vertex Pharmaceuticals’ new cell and genetic therapies center in Boston’s Seaport District. 

The 268,000-square-foot facility at 6 Tide St. will contain large molecule R&D labs, clinical-scale manufacturing operations, analytical and microbiology labs, general office space, support operations, bulk gas storage and staff amenities. 

In addition to achieving LEED certification, the manufacturing operations will meet cGMP (current good manufacturing practices) requirements and ISO classifications. TRIA will be responsible for lab, office, and amenity design, while working closely with the entire project team. 

Members of the project team include process architect and engineer Jacobs, BR+A Consulting Engineers, McNamara Salvia Structural Engineers, code consultant Cosentini Associates, LEED consultant Thornton Tomasetti and Kyle Zick Landscape Architecture. 

They Said It: 

“TRIA is thrilled to be working alongside the Vertex project team to design this new facility for Vertex Cell and Genetic Therapies. We are proud to be supporting Vertex and their mission to bring these cutting-edge therapies to patients.”
— TRIA Managing Principal Sherwood Butler